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Abstract
Background: Platelet-activating factor (PAF; 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a lipid mediator
derived from cell membrane. It has been reported that PAF is involved in various pathological conditions, such as
spinal cord injury, multiple sclerosis, neuropathic pain and intrathecal administration of PAF leads to tactile
allodynia. However, the expression of PAF synthases and its receptor in the spinal cord following peripheral nerve
injury is unknown.
Methods: Using the rat spared nerve injury (SNI) model, we investigated the expression of PAF synthases (LPCAT1
and 2) and PAF receptor (PAFr) mRNAs in the spinal cord. Reverse transcription polymerase chain reaction (RT-PCR)
and double-labeling analysis of in situ hybridization histochemistry (ISHH) with immunohistochemistry (IHC) were
employed for the analyses. Pain behaviors were also examined with PAFr antagonist (WEB2086).
Results: RT-PCR showed that LPCAT2 mRNA was increased in the ipsilateral spinal cord after injury, but not
LPCAT1 mRNA. Double-labeling of ISHH with IHC revealed that LPCAT1 and 2 mRNAs were constitutively expressed
by a subset of neurons, and LPCAT2 mRNA was increased in spinal microglia after nerve injury. RT-PCR showed
that PAFr mRNA was dramatically increased in the ipsilateral spinal cord after nerve injury. Double-labeling analysis
of ISHH with IHC revealed that after injury PAFr mRNA was predominantly colocalized with microglia in the spinal
cord. Continuous intrathecal administration of the PAFr antagonist suppressed mechanical allodynia following
peripheral nerve injury. Delayed administration of a PAFr antagonist did not reverse the mechanical allodynia.
Conclusions: Our data show the histological localization of PAF synthases and its receptor in the spinal cord
following peripheral nerve injury, and suggest that PAF/PAFr signaling in the spinal cord acts in an autocrine or
paracrine manner among the activated microglia and neurons, thus contributing to development of neuropathic
pain.
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Background
Peripheral nerve injury can cause neuropathic pain syn-
dromes characterized by both spontaneous and evoked
painful sensations. Although it is thought that plastic
alterations in central or peripheral neuronal processing
play important roles in the development of neuropathic
pain [1-5], the underlying molecular mechanisms are
not fully understood. Accumulated evidence shows that
glial cells in the spinal cord significantly contribute to
neuropathic pain [6,7] and that after peripheral nerve
injury activated glial cells produce several inflammatory
molecules [8]. Recently, we have reported that leuko-
trienes, one of the lipid mediators produced by glial
cells, are involved in the development of neuropathic
pain following peripheral nerve injury [9].
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medium, provided the original work is properly cited.The platelet-activating factor (PAF; 1-alkyl-2-acetyl-
sn-glycero-3-phosphocholine) is a lipid mediator
derived from cell membrane and implicated in a vari-
ety of physiological and pathological conditions
[10-12]. LysoPAF, a precursor of PAF, is produced
from glycerophospholipid cleaved by Ca
2+-dependent
cytosolic phospholipase A2 (cPLA2). LysoPAF is
converted to PAF by lysophosphatidylcholine acyl-
transferase 1 (LPCAT1) or acetyl-CoA:lyso-PAF acet-
yltransferase/lysophosphatidylcholine acyltransferase 2
(LPCAT2) enzymatically [13,14]. PAF binds the PAF
receptor (PAFr) that coupled to G proteins Gi, Gq,
and G12/13. Activation of PAFr results in the mobili-
zation of intracellular Ca
2+, inhibition of cyclic AMP
formation and the activation of mitogen-activated pro-
tein kinases. Thus, it appears that PAFr can induce a
variety of intracellular signaling pathways that evoke
wide range of biological functions [10,15,16].
In the nervous system, PAF is involved in pathological
conditions, such as ischemia-reperfusion injury, spinal
cord injury and multiple sclerosis [17-19]. Several
reports have suggested a role of the PAF/PAFr system
in modulating pain signaling in the peripheral nervous
system. PAF is involved in ultraviolet B irradiation-
induced hyperalgesia in the rat hindpaw [20] and intra-
plantar injection of PAF induced hypersensitivity in
response to noxious stimuli [21,22]. Recently, Hasegawa
et al. have demonstrated that dorsal root ganglion
(DRG) neurons express LPCAT2 and macrophages
around the DRG neurons express PAFr after peripheral
nerve injury. The underlying mechanism of pain signal-
ing induced by PAF in the peripheral nervous system is
that the activation of PAFr may produce several proin-
flammatory cytokines after nerve injury [23]. In the cen-
tral nervous system, it has also been reported that PAF
is implicated in the induction of pain behaviors. Morita
et al. have demonstrated that intrathecal injection of
PAF produced potent tactile allodynia in mice, suggest-
ing that PAF in the spinal cord may be a mediator of
neuropathic pain following peripheral nerve injury
[24,25]. The expression of PAF synthases and PAFr in
the spinal cord is unknown and accumulating evidence
has led us to investigate the histological evidence of
PAF synthases and PAFr in spinal cord and to study
whether the PAF/PAFr pathway plays a role in neuro-
pathic pain induced by peripheral nerve injury. The pur-
pose of present study was to examine the detailed
expression pattern of PAF synthases and its receptor in
the rat spinal cord after nerve injury and to confirm
their roles in neuropathic pain.
Results
Peripheral nerve injury increases LPCAT2 mRNA in spinal
microglia
To examine whether the induction of PAF synthase
mRNAs in rat spinal cord occurs after nerve injury, we
first investigated reverse transcription polymerase chain
reaction (RT-PCR) for LACAT1 and LPCAT2 mRNAs
in L4-L5 ipsilateral spinal cord tissue that received
spared nerve injury (SNI) surgery (n = 4, each time
point). RT-PCR revealed that LPCAT2 was significantly
increased at 3 days after nerve injury (Figure 1A, B).
LPCAT1 mRNA did not change after SNI surgery (Fig-
ure 1A, B). We examined the expression pattern of
LPCAT1 in the spinal cord of naive and 3 days after
nerve injury using in situ hybridization histochemistry
(ISHH) with radioisotope-labeled probes (Figure 1C, D).
In the spinal cord of naive rats, we detected LPCAT1
mRNA signals throughout the spinal cord (Figure 1C).
As predicted from the RT-PCR analysis, the expression
of LPCAT1 mRNA was not changed after nerve injury
(day 3) compared to naive rats using ISHH (Figure 1D).
Next, we demonstrated the distribution of mRNA for
LPCAT2 in the spinal cord after SNI surgery (Figure 1E,
F). We detected signals for LPCAT2 in both white and
gray matter of the naive rat spinal cord (Figure 1E) and
the LPCAT2 mRNA was significantly increased at 3
days after surgery on the ipsilateral side (Figure 1F). The
aggregation of grains occurred in cells with small nuclei
stained by hematoxylin (data not shown). To character-
ize the LPCAT1 and LPCAT2 mRNA-expressing cells in
the spinal cord after SNI (day 3), we performed double-
labeling analysis of ISHH with immunohistochemistry
(IHC) for NeuN, GFAP and Iba1 (Figure 2). We found
that hybridization signals for LPCAT1 mRNA were pre-
dominantly localized in NeuN-positive cells, but not
GFAP or Iba1-positive cells, thus indicating that the
LPCAT1 expression was in neurons (Figure 2A-C).
LPCAT2 mRNA-expressing cells were not labeled by
GFAP immunoreactivity (Figure 2E). The LPCAT2
mRNA-expressing cells were double-labeled with a
small number of NeuN-positive cells both in the con-
tralateral (data not shown) and ipsilateral spinal dorsal
horn after nerve injury. In contrast, LPCLT2 mRNA
positive signals were heavily colocalized with Iba1
immunoreactivities in the dorsal horn ipsilateral to the
injury (Figure 2F). Therefore, these data suggest that
both LPCAT1 and 2 mRNAs were constitutively
expressed in a small subset of neurons and LPCAT2
was predominantly increased in microglia following per-
ipheral nerve injury.
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microglia after peripheral nerve injury
The expression of PAFr mRNA in the spinal cord was
also examined by RT-PCR analysis. RT-PCR revealed
that mRNA of PAFr significantly increased, peaked at 7
days and continued at least for 14 days after nerve
injury (Figure 3A). In order to determine the expression
pattern of PAFr mRNA, we performed ISHH in the
spinal cord after peripheral nerve injury using ISHH. As
predicted from the RT-PCR analysis, the expression of
Figure 1 Peripheral nerve injury (SNI) up-regulates LPCAT2 mRNA in the ipsilateral spinal cord. (A) Gel panels show PCR products from
the ipsilateral L4-L5 spinal cord taken from 0 (naive), 1, 3, 7 and 14 days after nerve injury. (B) Graphs show quantification of the relative mRNA
levels of LPCAT1 and LPCAT2. LPCAT1 and LPCAT2 mRNA levels were normalized against GAPDH (n = 4, mean ± SEM, #; p < 0.05 compared
with naive). (C-F) Darkfield images of ISHH revealed the mRNA expression of LPCAT1 (C, D) and LPCAT2 (E, F) in naive rats (C, E) and 3 days after
nerve injury (D, F). Calibration bar: 500 μm.
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eral dorsal and ventral horn at 7 days after nerve injury
compared with naive rats (Figure 3B, C). The labeled
cells for PAFr mRNA contained small nuclei deeply
stained by hematoxylin (data not shown). To elucidate
the cell type of PAFr mRNA positive cells, we carried
out the double-labeling study of ISHH with IHC (Figure
3D-F). The double-labeling analysis revealed that the
induction of PAFr mRNA in the spinal cord occurred in
cells labeled for Iba1 at 7 days after nerve injury (Figure
3F), not in those labeled with NeuN or GFAP (Figure
3D, E). These data suggested that PAFr mRNA was
exclusively expressed in microglia in the ipsilateral
spinal cord after nerve injury.
Intrathecal administration of PAF receptor antagonist
reduced mechanical allodynia induced by peripheral
nerve injury
The presence of the mRNA of synthases and the recep-
tor for PAF in the spinal cord after nerve injury led us
to behavioral experiments to examine whether PAF has
a role in neuropathic pain. The effect of an intrathecal
injection of the PAFr antagonist (WEB2086) was exam-
ined using the SNI model (Figure 4). WEB2086 has
been used as a specific antagonist for PAFr [24]. An
osmotic pump was set and the administration of antago-
nist started from 2 days after SNI surgery. The nerve
injury decreased the withdrawal threshold on the ipsilat-
eral side indicating mechanical allodynia. The early
administration of the PAFr antagonist (2.4 nmol/d) atte-
nuated the mechanical allodynia significantly compared
to the vehicle-treated group (Figure 4A). A low dose of
the PAFr antagonist (0.24 nmol/d) partially prevented
the mechanical allodynia induced by peripheral nerve
injury (Figure 4A). The delayed administration of the
PAFr antagonist from 6 days after SNI failed to suppress
pain behaviors (Figure 4C). On the contralateral side to
the nerve injury, both the early and delayed administra-
tion of PAFr antagonist did not have any effect on the
withdrawal threshold (Figure 4B, D). These findings
i n d i c a t e dt h a tP A Fh a sar o l ei nt h ed e v e l o p m e n to f
neuropathic pain following peripheral nerve injury.
Figure 2 LPCAT2 mRNA is increased by spinal microglia after SNI surgery. Bright-field images of combined ISHH for LPCAT1 (A-C) and
LPCAT2 (D-F) with IHC for NeuN (A, C), GFAP (B, E) and Iba1 (C, F) at 3 days after SNI surgery. Open arrows indicate double-labeled cells.
Arrowheads indicate single-labeled cells by ISHH (aggregation of grains), and open arrowheads indicate single immunostained cells (brown
staining). Calibration bar: 20 μm.
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no effects on the microglia activation and activation of
p38 MAPK activation
In order to examine the role of PAFr in microglia, we
investigated whether intrathecal PAFr antagonist could
attenuate microglia activation and p38 MAPK expres-
sion in the spinal cord after nerve injury (Figure 5).
Immunostaining of Iba1 showed the activation of micro-
glia in the ipsilateral spinal cord to the injury (Figure
5A, B). In the same series of the spinal cord sections,
we observed the injury-induced phosphorylation of p38
MAPK (Figure 5D, E). Intrathecal chronic administra-
tion of WEB2086 (2.4 nmol/d) from 1 to 3 days after
nerve injury did not attenuate the number and intensity
of the staining of Iba1 and phosphorylation of p38
MAPK in the spinal cord after nerve injury (Figure 5C,
F). Activation of p38 MAPK was examined by Western
blot technique (Figure 5G-J). The chronic intrathecal
a d m i n i s t r a t i o no fW E B 2 0 8 6( 2 . 4n m o l / d )f r o m1t o3
days (Figure 5G, I) and 1 to 7 days (Figure 5H, J) did
not suppress the phosphorylation of p38 MAPK in the
spinal cord.
Discussion
The present study demonstrated the following new find-
ings: (1) Peripheral nerve injury induces mRNA for
LPCAT2 but not LPCAT1. LPCAT1 mRNA was loca-
lized in spinal cord neurons. LPCAT2 mRNA was con-
stitutively expressed in a small subset of neurons and
the increase of mRNA expression of LPCAT2 occurred
in spinal microglia, shown by double-labeling analysis of
ISHH with IHC. (2) The PAFr is dramatically increased
in the spinal cord after nerve injury. The double labeling
analysis reveals that PAFr in the dorsal and ventral horn
was predominantly colocalized with microglia. (3) Con-
tinuous intrathecal injection of a PAFr antagonist signif-
icantly inhibits the decrease in withdrawal threshold to
mechanical stimuli after peripheral nerve injury. (4) The
Figure 3 Peripheral nerve injury enhances the expression of mRNA for PAF receptor in ipsilateral spinal microglia. (A) Upper panels
show PCR products from the ipsilateral L4-L5 spinal cord taken from 0 (naive), 1, 3, 7 and 14 days after nerve injury. Lower graphs show the
statistical quantification of the relative mRNA levels of PAFr. PAFr mRNA level was normalized against GAPDH (n = 4, mean ± SEM, #; p < 0.05
compared with naive). (B, C) Darkfield photographs reveal the ISHH for PAFr mRNA expression in the spinal cord taken from naïve rats (B) or 7
days (C) after SNI surgery. (D-F) Characterization of SNI-induced PAFr mRNA in the spinal dorsal horn. Brightfield photographs of combined ISHH
for PAFr with IHC for NeuN (D), GFAP (E) and Iba1 (F) at 7 days after injury. Open arrows indicate double-labeled cells. Arrowheads indicate
single-labeled cells by ISHH (aggregation of grains), and open arrowheads indicate single immunostained cells (brown staining). Calibration bars:
darkfield images; 500 μm, brightfield images; 20 μm.
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ate pain behaviors following SNI surgery. Our findings
indicate that PAF is produced by microglia and neurons
and received by microglia following peripheral nerve
injury. Therefore, we postulate that PAF signaling via
the PAFr among microglia and neurons may be involved
in the development of mechanical allodynia after periph-
eral nerve injury.
PAF, an alkyl-phospholipid, was identified as a plate-
let-aggregating factor derived from eosinophils [26] and
its receptor was cloned by Honda et al. [15]. Accumulat-
ing evidence indicates that lipid mediators, such as lyso-
phosphatidic acid (LPA), prostaglandins (PGs) and
leukotrienes (LTs) play an important role in neuropathic
pain following peripheral nerve injury [9,27,28]. PAF
have also been considered an important molecule
involved in pathological conditions in the nervous sys-
tem, such as ischemia-reperfusion injury, spinal cord
injury and inflammatory pain [17,18,20]. Furthermore,
using PAF receptor-knockout mice, Tsuda et al.
reported that PAFr signaling may be involved in produ-
cing persistent pain through the mitogen-activating pro-
tein kinase (MAPK) in primary afferent neurons after
peripheral nerve injury [29]. Intrathecal injection of PAF
induced pronounced tactile allodynia, thus suggesting
that PAF in the spinal cord may be a mediator of neuro-
pathic pain [24,25]. One important question is which
cells produce the PAF and which cells are receptive to
PAF in the spinal cord after peripheral nerve injury.
There are few reports indicating the localization of PAF
synthases and PAFr in vitro and in vivo. It has reported
that LPCAT2 is expressed in primary cultured murine
microglia and astrocytes [30] but not neurons derived
from brain, and PAFr was found to be expressed in
microglia and neurons in the rat hippocampus [31]. In
the present study, we demonstrated that LPCAT2
mRNA was expressed in microglia and neurons (Figure
2D, F), and PAFr mRNA induced by peripheral nerve
injury was exclusively co-localized with microglia in the
spinal cord (Figure 3F). This discrepancy may be due to
Figure 4 Intrathecal administration of PAF receptor antagonist (WEB2086) significantly reduces the mechanical allodynia following
peripheral nerve injury. (A, B) The osmotic pump was set 2 days after nerve injury and drug administration continued for 7 days. (C, D) The
osmotic pump was implanted 6 days after SNI surgery and worked for 7 days. (B, D) The treatment with these drugs did not change the
mechanical sensitivity on the contralateral side. In all graphs, values are mean ± SEM (n = 6-7 in each group, # p < 0.05 compared with vehicle).
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the regions (hippocampus versus spinal cord).
Microglia, which are considered the macrophages of
the central nervous system, are bone marrow-derived
haematopoietic cells that infiltrate the central nervous
system during embryonic development. Microglia in the
spinal cord increase and become activated in the spinal
dorsal horn following peripheral nerve injury [32] and
activated microglia are known to produce several neuro-
trophic factors and proinflammatory cytokines, such as
brain-derived neurotrophic factor (BDNF), IL-1ß, IL-6
and TNF-alpha, and are involved in the pain hypersensi-
tivity [33-36]. In this study, we showed that PAFr was
increased after nerve injury and was predominantly
located in microglia in the spinal cord. Recently, it has
reported that macrophages around the DRG express
PAFr and produce TNF-alpha and IL-1ß after peripheral
nerve injury [23]. Our results in the context of previous
findings suggest that PAFr is a trigger for the produc-
tion of proinflammatory cytokines.
Another important question is which intracellular sig-
naling pathway is activated by PAF via the PAFr after
nerve injury. Previous papers have shown that PAFr-
mediated intracellular signal transduction and PAFr may
couple with Gi or Gq proteins depending on cell type
[10]. It has been demonstrated that PAF-evoked p38
mitogen-activated protein kinase (MAPK) activation is
observed in CHO cells expressing PAFr [37]. A lot of
reports have defined that nerve injury activates the p38
MAPK cascade in microglia and the activation of p38
MAPK in the spinal microglia contributes to the genera-
tion of neuropathic pain [8,38,39]. However, we showed
here that PAFr inhibition did not affect on the microglia
activation and p38 MAPK phosphorylation in the doses
that could suppress neuropathic pain behavior (Figure
5). Taken together with the above-mentioned reports
and present study, it may suggest that PAFr activates
the signaling cascades that is independent of p38 MAPK
and involved in the production of proinflammatory cyto-
kines after peripheral nerve injury.
In the present study, findings that SNI surgery
induced upregulation of LPCAT2 and PAFr in spinal
microglia and intrathecal injection of PAFr antagonist
(WEB2086) significantly suppressed the development of
mechanical allodynia suggested an intraspinal role of
PAF in neuropathic pain. Because previous studies
reported that PAFr is increased in macrophages around
DRG in the peripheral nervous system and is involved
in hyperalgesia in neuropathic pain condition [23], we
could not rule out the possibility that intrathecal injec-
tion of PAFr antagonist inhibited the activation of PAFr
expressed in macrophages around the DRG. Therefore,
we considered that both PAFr expressed by microglia in
spinal cord and by macrophages around DRG might be
important for neuropathic pain. The delayed administra-
tion of PAFr antagonist fail to suppress neuropathic
pain related behaviors, suggesting that once PAFr were
activated, the downstream signals may turn on the irre-
versible activation and facilitate the production of proin-
flammatory cytokines. Our finding indicated that PAF
Figure 5 Intrathecal administration of PAF receptor antagonist
(WEB2086) did not affect on the microglia activation and
phosphorylation of p38 MAPK following peripheral nerve
injury. (A-C) Immunohistochemistry of Iba1 in the spinal cord of
rats that received chronic administration of saline (A, B) and
WEB2086 (C) in the contralateral (A) and ipsilateral side (B, C) of
dorsal horn at 3 days after SNI surgery. (D-F) Immunohistochemistry
of p-p38 in the spinal cord of SNI model rats with saline (D, E) and
WEB2086 (F) administration in the contralateral (D) and ipsilateral
side (E, F) of dorsal horn at 3 days after SNI surgery. (G-J) Western
blot analysis of p-p38 MAPK in the spinal cord after peripheral nerve
injury. (G, H) Immunoreactive membrane panels show p-p38 MAPK
in the L4, 5 spinal cords at 3 days (G) and 7 days after injury (H). (I,
J) Graph shows the protein levels of p-p38 expressed as
percentages of the protein level in the normal control spinal cord
(mean ± SEM; each time points n = 4,). * indicates p < 0.05
(ANOVA) compared to naïve control.
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after nerve injury as well as other molecules synthesized
by activated microglia.
On the other hand, we detected that LPCAT1 and 2
mRNA were constitutively expressed in a subset of
spinal neurons. LPCAT1 and 2 have lysophosphatidyl-
choline acyltransferase activity, which is involved in
remodeling of the cell membrane [14,40]. LPCAT1 and
2 in the spinal cord neurons of naive rats, therefore,
may constitutively catalyze the cell membrane in the
remodeling pathway and also can convert lyso-PAF to
PAF. And it has been reported that cPLA2 and LPCAT2
were activated by the increase of intracellular Ca2+ con-
centration, but not LPCAT1 [14,41]. It is believed that
not only in primary afferent neurons, but also in spinal
neurons, Ca
2+ concentration is up-regulated after per-
ipheral nerve injury [42,43]. After SNI surgery, therefore,
we presume that the increase of PAF production could
be produced by spinal neurons via activation of
LPCAT2. The PAF/PAFr signaling may involve neuron/
glia communication after nerve injury.
Conclusions
In summary, the present study indicates that PAF is
produced by spinal microglia and neurons, and is
received by microglia after peripheral nerve injury. We
propose that PAF/PAFr signaling in the spinal cord may
act in an autocrine or paracrine manner among the acti-
vated microglia and neurons, thus increasing mechanical
hypersensitivity.
Methods
Animal procedures
Male Sprague Dawley rats weighing 200-250 g were
anesthetized with sodium pentobarbital (50 mg/kg, i.p.)
and received spared nerve injury (SNI) [44]. The
wounds were closed, and the rats were allowed time to
recover. At several time points (0, 1, 3, 7 and 14 d) after
the SNI, groups of rats were processed for histological
analysis (n = 4 at each time point). Every effort was
made to minimize animal suffering and reduce the num-
ber of animals used. All animal experimental procedures
were approved by the Hyogo College of Medicine Com-
mittee on Animal Research (#A11-051) and were per-
formed in accordance with the National Institutes of
Health guidelines on animal care.
Reverse transcription-polymerase chain reaction (RT-PCR)
and in situ hybridization histochemistry (ISHH)
The rats were killed by decapitation under deep ether
anesthesia. The ipsilateral of spinal cords (L4-L5) were
removed and rapidly frozen with powdered dry ice and
stored at -80°C until use. Extraction of total RNA was
done using a single step extraction method with
ISOGEN (Nippon Gene, Tokyo, Japan) as described in a
previous paper [45]. PCR primers for PAF synthases,
PAF receptor and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) cDNA were designed as follows:
LPCAT1 (accession number NM_001100735) primers,
sense 5’-CCATCCGGCTCCTGTTTGCT-3’ and anti-
sense 5’-CGCCCGTCGCTTGATCTCTT-3’;
LysoPAFAT/LPCAT2 (accession number
XM_001064713) primers, sense 5’-CCTCGCCAGGC
GTCCTTCTT-3’ and antisense 5’-GAACATGGCAC-
GACCCAGGA-3’;
PAF receptor (accession number U04740) primers,
sense 5’-GGCTCCTTCCGTGTGGATTC-3’ and anti-
sense 5’-GCAGCGGGTGATGTTACCTG-3’;
GAPDH (accession number M17701) primers, sense
5’- CCAGGGCTGCCTTCTCTTGT -3’ and antisense
5’- CCAGCCTTCTCCATGGTGGT -3’.
The resulting PCR products were used to generate the
cRNA probes for ISHH. The rats were killed by decapi-
tation under deep ether anesthesia. The bilateral L4-L5
spinal cord were dissected out, rapidly frozen in pow-
dered dry ice, and cut on a cryostat at a 10 μmt h i c k -
ness. The protocol for ISHH was base on a publish
method [46]. Using the enzyme-digested clones,
35S
UTP-labeled antisense and sense cRNA probes were
synthesized. The
35S-labeled probes in hybridization buf-
fer were placed on the section, and then incubated at
55°C overnight. Sections were then washed and treated
with 1 μg/ml RNase A. Subsequently, sections were
dehydrated and air-dried. After the hybridization reac-
tion, the slides were coated with NTB emulsion (Kodak,
Rochester, NY, USA) and exposed for 5-6 weeks. Once
developed in D-19 (Kodak), the sections were stained
with hematoxylin-eosin and coverslipped.
Double-labeling analysis of in situ hybridization with
immunohistochemistry
To examine the distribution of mRNAs for PAF
synthases and its receptor in neurons versus glial cells,
we used a combined ISHH with immunohistochemistry
(IHC). The frozen spinal cord sections were processed
for IHC using the ABC method [47]. The following anti-
bodies for double-labeling analysis were used: rabbit
anti-ionized calcium-binding adapter molecule1 (Iba1)
polyclonal antiserum (1:100; Wako Chemicals, Tokyo,
Japan), mouse anti-neuronal specific nuclear protein
(NeuN) monoclonal antiserum (1:2000; Chemicon,
Temecula, CA), and rabbit anti-glial fibrillary acidic pro-
tein (GFAP) polyclonal antiserum (1:2000; DakoCytoma-
tion, Glostrup, Denmark). Several markers were
visualized as brown signals by 0.05% 3, 3-diaminobenzi-
dine tetrahydrochloride (DAB; Sigma) containing 0.01%
hydrogen peroxidase without nickel sulfate. After IHC,
these sections were immediately processed for ISHH. A
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methods of double labeling with IHC and ISHH were
described previously [48].
Fluorescence immunohistochemistry
IHC was performed as described before [49]. The tissue
was frozen in powdered dry ice, cut on a cryostat at a
25 μm thickness. The following antibodies were used for
IHC: rabbit anti phosphorylated p38 polyclonal anti-
serum (1: 1000, Cell signaling MA, USA), goat anti Iba1
polyclonal antiserum (1:500, Abcam, Cambridge, MA).
In brief, spinal cord sections were incubated with a pri-
mary antibody over night at 4°C and followed by sec-
ondary antibodies; anti rabbit Alexa Fluor 488 IgG (1:1,
000; Invitrogen, San Diego, CA), anti goat Alexa Fluor
594 IgG after incubation with respective primary
antibodies.
Western blot
The spinal samples preparation and Western blotting
were performed as described before [49]. Membranes
were incubated with Blocking One P (Nakarai, Kyoto,
Japan) in Tris buffer containing Tween 20 (TBST) (10
mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.2% Tween
20) for 20 min at room temperature and incubated with
the polyclonal primary antibody for phosphorylated p38
(1:2000; Cell signaling) at 4°C overnight. Membranes
were then washed twice with TBST and probed with
goat anti-rabbit IgG conjugated with alkaliphosphatase
(1:2000, Chemicon) at room temperature for 2 h and
visualized by chemiluminescence using CDP-star ready-
to-use reagent (Roche, Indianapolis, USA). The loading
and blotting of the amount of protein was verified by
reprobing the membrane with anti-b-actin antiserum
(1:2000; Sigma). Films were scanned and quantified
using NIH Image, version 1.61 and normalized against a
loading control (beta-actin). Data are expressed as mean
± SEM. Differences in changes of values over time of
each group were tested using one-way ANOVA, fol-
lowed by individual post hoc comparisons (Fisher’s
exact test). A difference was accepted as significant if p
< 0.05.
Drug treatments
Two or six days after SNI surgery, the L5 vertebra was
laminectomized under adequate anesthesia with sodium
pentobarbital, and a soft tube (Silascon, Kaneka Medix
Company, Osaka, Japan; outer diameter, 0.64 mm) filled
with 5 μl of saline was inserted into the subarachnoid
space for an ~0.5 cm length (tube were pointed caud-
ally). Mini-osmotic pumps (model 2001; 7 days pump, 1
μl/h, Alzet Corporation, Palo Alto, CA) filled with saline
or PAFr antagonist (WEB2086) [4-[3-[4[(2-Chlorophe-
nyl)-9-methyl-6H-thieno[3, 2-f][1,2,4]triazolo[4, 3-a]
diazepin-2-yl]-1-oxopropyl]morpholine]] (Tocris
Bioscience, MO, USA) were connected to the tube.
Then, the pump was laid under the skin and the inci-
sion was closed. The concentrations of WEB2086 was
0.24 nmol/day and 2.4 nmol/day diluted in 10%
dimethyl sulfoxide (DMSO) (n = 6-7, for behavior test).
Behavioral tests
All SNI rats were tested for mechanical allodynia on the
plantar surface of the hindpaw 1 day before surgery and
1, 3, 5, 7, 9, 11 and 14 days after surgery. Mechanical
allodynia was assessed with a dynamic plantar anesthesi-
ometer (Ugo Basile, Comerio, Italy), which has an auto-
mated von Frey-type filament (0.5 mm diameter) [50,51].
The detailed method of mechanical sensitivity measure-
ment in rat hindpaw was described previously [49].
Statistics
Data are expressed as mean ± SEM. Differences in
changes of values over time of each group were tested
using one-way ANOVA, followed by individual post hoc
comparisons (Fisher’s exact test) or pair-wise compari-
sons (t test) to assess differences of values between
naive versus each time point of the SNI groups. A dif-
ference was accepted as significant if p < 0.05.
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